Major tasks for Carl Gordon of OrbiMed, a healthcare fund, include drug pricing and helping to turn promising ideas into reality, as he tells LSIPR.
One of the challenges facing healthcare venture capital firms is the pressure concerning drug pricing.
“We need companies to be able to charge a reasonable amount of money for the drugs because, if they can’t, we can’t make returns,” says Carl Gordon, founding partner and co-head of global private equity at OrbiMed.
“It’s easy to criticise pharmaceutical companies for charging a lot for their drugs, so that’s one issue we have to deal with,” he adds.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
LSIPR 50 2017, venture capital firms, drug pricing, pharmaceutical companies, OrbiMed, Johnson & Johnson, AstraZeneca,pharmaceutical
